[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565232":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":51,"collaborators":12,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":12,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":12,"enrollmentInfo":62,"targetDuration":12,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":36,"whyStopped":12,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Chicago","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Peri-incisional local anesthesia","NO_INTERVENTION","subjects randomized to peri-incisional local anesthesia administration will receive an injection of 25 ml of 0.25% bupivacaine across all incisions at the time of wound closure (standard of care)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Genicular nerve blockade","EXPERIMENTAL","Subjects randomized to genicular nerve block will receive a fluoroscopic guided injection of 5 ml of 0.25% bupivacaine at the described locations of the superolateral genicular nerve, super medial genicular nerve, inferomedial genicular nerve, recurrent fibular nerve, and infrapatellar branch of the saphenous nerve under fluoroscopic guidance at the time of wound closure",[18],"Drug: Bupivacain",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Bupivacain","5mL 0.25% bupivacain",[14],[26],{"name":27,"affiliation":5,"role":28},"Anthony Christiano, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":12,"email":33},"CONTACT","773-834-3531","anthony.christiano@bsd.uchicago.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Chicago","Illinois","60637","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-87.65005,41.85003,{"lat":46,"lon":45},[49,50],{"name":27,"role":31,"phone":12,"phoneExt":12,"email":33},{"name":27,"role":28,"phone":12,"phoneExt":12,"email":12},{"type":52,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100565232","phase-1-genicular-nerve-block-after-open-reduction-internal-fixation-of-tibial-plateau-100565232",false,"NCT06639503","Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau","Genicular Nerve Block for Analgesia After Open Reduction Internal Fixation of Tibial Plateau Fractures: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n• Any adult patient (ages 18 and over) undergoing open reduction internal fixation of an acute isolated tibial plateau fracture\n\nExclusion Criteria:\n\n* Subjects younger than 18\n* Polytraumatized Subjects\n* Subjects with pathologic fractures\n* Subjects with tibial plateau fractures treated nonoperatively\n* Subjects with tibial plateau fractures treated operatively but with re-operations at the same site\n* Subjects with open fractures\n* Subjects with fracture-dislocations\n* Subjects with active or history of anxiety\n* Subjects with visual analog scale anxiety score ≥ 7 measured preoperatively\n* Subjects with chronic pain syndromes\n* Subjects with chronic opioid use\n* Subjects with illicit drug use disorder\n* Subjects with alcohol abuse disorder\n* Subjects with kidney disease precluding use of ketorolac\n* Subjects with liver disease precluding the use of acetaminophen\n* Subjects with allergy to acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opiates or local anesthesia\n* Subjects with inability to provide a visual analog scale score postoperatively\n* Subjects with contraindications to receiving peripheral nerve blocks, including relevant neurologic deficits, active infection at sites of injections - re-operation at the same site","ALL","18 Years",{"count":63,"type":64},38,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control.",[70],"Tibial Plateau Fractures",[72,73,70,74],"peri-incisional local anesthesia","genicular nerve block","open reduction internal fixation","2026-02-04",{"date":77,"type":78},"2026-02-05","ACTUAL",{"date":80,"type":78},"2024-11-01",{"date":82,"type":64},"2026-10-14",{"name":5,"class":6},1]